A hot ASX stock with 'multiple catalysts' looming is 8% down. Time to buy

The Blackwattle team is still bullish on these pharmaceutical shares despite a recent sell-off.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's funny to call an ASX stock that's rocketed 217% in the past year a "bargain".

But that's precisely the situation we have with Neuren Pharmaceuticals Ltd (ASX: NEU), according to the experts at Blackwattle.

Let's check out their rationale:

'A pause for breath'

The Neuren share price has plunged 8.2% since late December.

But the simple fact is that the Blackwattle team is not worried.

"Neuren fell 5% in January, which we saw as a pause for breath, after rising 115% over the previous 3 months," read its memo to clients.

The steep climb in the preceding quarter was due to multiple factors.

"The rise over the previous three months was driven by the release of strong revenue growth from Daybue, their sole approved drug treating Rett Syndrome in the US and positive phase 2 trial results for their new drug NNZ-2591."

The new drug development is critical in the Blackwattle team's continued bullishness.

"The phase 2 results for NNZ-2591 were particularly exciting and provide strong confidence for NNZ-2591 to progress towards a phase 3 trial."

A huge 2024 expected for this ASX stock

Blackwattle experts are far from the only ones not at all put off by either the massive rise in the past year or the diving stock price over the past six weeks.

Broking platform CMC Invest shows all five analysts covering Neuren still rating the stock as a buy.

"We continue to retain a large position in the company given the multiple value accretive upcoming catalysts in 2024," read the memo.

"The key drivers for the portfolio tend to be fundamental company updates which give high quality companies the opportunity to demonstrate their ongoing strength and the market can reassess the outlook and what to pay for it."

Neuren Pharmaceuticals is scheduled to release its preliminary financial results on 23 February.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Growth Shares

3 ASX 200 shares that have returned more than 17% a year over the last decade

These shares demonstrate why buy and hold investing can be a great strategy for investors.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Growth Shares

2 ASX growth shares with rapidly-rising dividends to buy now

Rapidly growing businesses are appealing for multiple reasons.

Read more »

a man in a green and gold Australian athletic kit roars ecstatically with a wide open mouth while his hands are clenched and raised as a shower of gold confetti falls in the sky around him.
Growth Shares

3 amazing Australian stocks to buy and hold until 2030

Analysts think these shares could be high-quality options for investors looking for long term picks.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Growth Shares

Why these ASX 200 growth shares could rise 40% in 12 months

Analysts are tipping these shares to deliver big returns over the next 12 months.

Read more »

A woman makes the task of vacuuming fun, leaping while she pretends it is an air guitar.
Opinions

Opinion: This is one of the best ASX growth shares to own for the next 5 years

This stock is rapidly growing, and I’m excited about it.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Growth Shares

Buy Xero and this ASX 200 growth share in February

Analysts have good things to say about these growing companies.

Read more »

happy investor, share price rise, increase, up
Growth Shares

Buy these ASX growth shares with $3,000 in February

Analysts think these growth shares could be great options for investors with money to put into the share market.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Growth Shares

2 no-brainer ASX All Ords shares to buy with $2,000

Analysts have good things to say about these stocks. Let's see why they are so bullish.

Read more »